/ EN

Yufan Bio Partners with Pittsburgh's Abound to Develop Novel CAR-T Therapies

  • Categories:Company News
  • Author:Xi'an Yufan
  • Origin:Write for yourself
  • Time of issue:2020-09-18 23:36
  • Views:

Yufan Bio Partners with Pittsburgh's Abound to Develop Novel CAR-T Therapies

  • Categories:Company News
  • Author:Xi'an Yufan
  • Origin:Write for yourself
  • Time of issue:2020-09-18 23:36
  • Views:
Information

Yufan Bio, a Xi'an clinical-stage CAR-T company, partnered with Abound Bio of Pittsburgh to develop novel CAR-T technologies. The two companies will explore the use of HPK1 (hematopoietic progenitor kinase 1) inhibitors to make CAR-T therapies more effective. HPK1 has been shown to promote CAR-T exhaustion in research done by Xuebin Liao, PhD, Professor of Pharmaceutical Science at Tsinghua Universityand a Yufan co-founder. Yufan is working to inhibit HPK1 via gene knockout or small-molecule inhibitors. More details.... 

 

 

This article is available for purchase - please click here for details.

 

Sorry this page is available to subscribers only.

If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

 

 

imgboxbg

Home   丨   About Us   丨   Product and Pipeline   丨   Our Team   丨   News   丨   Career   丨   Contact

Address: 106 Fengze East Road, Nansha District, Guangzhou 
Email: ming-med@ming-med.com

Copyright © 2020 ming-med.com  保留所有权利  粤ICP备20029450号-1